What Сиофор 500 Treats: Main Uses and Benefits

The medication is commonly used to manage Type 2 Diabetes Mellitus, generally in patients who are overweight, when supportive control is needed alongside diet and exercise. It is applied across domains where additional symptomatic support is needed to address the chronic systemic imbalance of persistent high blood sugar. This treatment is relevant for easing the risks of severe complications associated with symptoms that create noticeable physiological strain. It provides a measure of support in managing the long-term risk and contributes to supporting the patient during episodes of heightened discomfort by addressing risks to systems and organs.

It is also commonly used to help with metabolic dysfunction in specific contexts, addressing T2DM in children and adolescents (from 10 years of age) and providing symptomatic support for women with Polycystic Ovary Syndrome (PCOS). This approach is relevant for managing symptoms related to metabolic dysfunction and hormonal irregularity.

“This supportive benefit contributes to improved comfort and supports general well-being during symptomatic phases.”

Quick Fact: Support for Metabolic Health Siofor 500 is applied in conditions involving metabolic dysfunction, supporting the management of high blood sugar and easing the risks of complications affecting the nerves, kidneys, and eyes.

Who can and cannot use Сиофор 500?

The eligibility for Siofor 500 (metformin) is strictly determined by regulatory authorities based on a patient’s health status, especially organ function, to minimize the risk of serious complications.

---

Category	Official Eligibility Status
Approved Populations	Adults and pediatric patients mathbf10 years of age and older with Type 2 Diabetes.
Absolute Contraindications	Severe Renal Impairment (eGFR below mathbf30 , mL/min/1.73 , m^2), Metabolic Acidosis (including diabetic ketoacidosis), known Hypersensitivity to metformin, and severe Hepatic Impairment.
Age-Related Restrictions	Children under 10 are not indicated for use. Older adults require more frequent renal function assessment, and initiation is generally not recommended in those ge mathbf80 unless renal function is confirmed normal.
Conditional Use	Use in Moderate Renal Impairment (eGFR 30–59 , mL/min/1.73 , m^2) is permitted but requires dose adjustments and monitoring.
Temporary Restrictions	The medicine must be discontinued temporarily before procedures involving iodinated contrast media (e.g., certain X-rays/scans) and before elective surgery involving general, spinal, or peridural anesthesia.
Pregnancy/Lactation	Use during pregnancy can be considered if clinically needed. Use during breastfeeding is generally not recommended by some regulators.

Interactions with other medicines and products are officially documented for Siofor 500 (metformin). The drug's interaction profile is primarily characterized by restrictions concerning procedures and substances that impact renal function and lactate metabolism, as outlined in government regulatory labels.

Formal restrictions dictate that the combination with iodinated contrast agents requires mandatory temporary discontinuation of metformin prior to or at the time of the procedure. Treatment cannot be restarted until at least 48 hours later, provided renal function has been confirmed as stable. Co-administration with acute alcohol intoxication is officially not recommended due to a significantly increased risk of lactic acidosis. This risk is noted to be potentiated in cases of fasting or hepatic impairment.

Pharmacokinetic interactions occur with certain cationic drugs that compete for renal transport systems. Inhibitors of OCT2/ MATE transporters, such as Cimetidine and Ranolazine, decrease metformin's renal clearance, leading to increased plasma concentration. Conversely, co-administration with food officially reduces the drug's peak plasma concentration and overall systemic exposure.

Pharmacodynamic interactions are documented for agents altering glucose homeostasis. Co-administration with Insulin or Insulin Secretagogues (e.g., sulfonylureas) presents an increased risk of hypoglycemia due to additive effects. Agents with intrinsic hyperglycaemic activity, like Glucocorticoids and Diuretics, may reduce metformin's efficacy. Additionally, long-term use is associated with a reduction in serum Vitamin B12 levels.

The active ingredient in Сиофор 500, Metformin, operates through multiple coordinated mechanisms to modulate glucose metabolism, primarily targeting the processes of glucose production and utilization.

Suppression of Endogenous Glucose Output

The core mechanism involves the inhibition of Mitochondrial Respiratory Chain Complex I in the liver, requiring the drug's transport into the cell via the OCT1 transporter. This action alters the cellular energy state, leading to the activation of the central metabolic enzyme, AMP-activated protein kinase ( AMPK). This cascade suppresses the activity of key enzymes involved in gluconeogenesis, resulting in a primary physiological effect of reducing the amount of glucose released by the liver into the bloodstream.

Modulation of Peripheral Glucose Utilization

The activation of AMPK extends beyond the liver to skeletal muscle and fat tissue. Here, this enzyme acts as a mediator, modulating the cellular signaling pathways that govern glucose uptake. This mechanism facilitates the translocation of GLUT4 transporters to the cell membrane, which increases the rate of glucose clearance from the circulation in peripheral tissues.

Administration Guidelines

Metformin, the active substance in Сиофор 500, is for oral administration in the form of an immediate-release (IR) tablet. The official dosing protocol mandates that the medicine be taken with or immediately after meals to support tolerability, and it is intended for long-term use as part of a treatment plan.

Treatment is initiated at a low dose, typically 500 mg once or twice daily, or 850 mg once daily. The dose is then slowly increased (titrated) based on assessment of blood glucose and patient tolerance, often in 500 mg weekly increments. The maximum approved daily dose for the IR formulation ranges from 2550 mg to 3000 mg, divided into two or three daily doses.

Population-Specific Use Rules

Population Group	Official Administration Rule
Pediatric (Age ge 10)	Starting dose is 500 mg twice daily; maximum daily dose is 2000 mg in divided doses.
Renal Function (eGFR)	Use is contraindicated if the estimated Glomerular Filtration Rate (eGFR) is below 30 mL/min/1.73 m^2. Initiation is not recommended if eGFR is 30 to 45 mL/min/1.73 m^2.
Missed Dose	If a dose is missed, it should be skipped, and the patient should resume the usual dosing schedule; two doses must not be taken to compensate.

The medicine is temporarily discontinued before or at the time of an iodinated contrast imaging procedure and can only be restarted after kidney function is re-evaluated and found to be stable.

Evidence for Use in Type 2 Diabetes Mellitus

Research exploring the use of metformin has been broad, primarily utilizing large-scale Randomized Controlled Trials (RCTs) and long-term prospective studies. These studies examined how the medicine was associated with changes in glycaemic control markers, such as average blood sugar levels, over defined time intervals. Research also included groups at high risk for developing T2DM, where the compound was studied for its role in managing that risk.

Outcomes Examined in T2DM Trials

Researchers tracked outcomes related to microvascular endpoints (affecting the eyes, kidneys, and nerves) and long-term cardiovascular endpoints (heart attack, stroke). While studies reported measurements of blood sugar control, the findings related to cardiovascular endpoints were mixed across different large research programs, and certainty remains low regarding these measurements when analyzed across the entire observed population.

Evidence in Women with Polycystic Ovary Syndrome (PCOS)

The medicine was evaluated in women with PCOS using short-term Randomized Controlled Trials and Meta-Analyses to explore outcomes related to systemic imbalance. Studies monitored reproductive health metrics, including ovulation rate and menstrual cycle regularity, alongside metabolic markers like insulin function. Findings indicate patterns related to shifts in these measurements during the study period.

Evidence in Special Populations

Research has explored the use of the medicine in children and adolescents (typically 10 through mid-teens) with Type 2 Diabetes, primarily using short-term RCTs that focused on measuring glycaemic control and Body Mass Index (BMI). Findings describe group patterns, but the evidence derived from this population is limited, and the measurements observed in children may be less sustained over time compared to adults.

What the Research Still Seeks to Clarify

Metformin has been the subject of studies extending over 20 years. However, the evidence highlights what is still uncertain. For all populations, long-term effects are not fully established regarding the prevention of every possible complication. Specifically, for youth, follow-up durations were limited, and the long-term measurements related to outcomes reflecting systemic or functional imbalance are not well characterized. Evidence quality varies across studies when analyzing specific complications, and subgroup findings are uncertain in many areas.

Key Studies & References

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
2. Long-term effects of lifestyle intervention or metformin on diabetes prevention: the Diabetes Prevention Program Outcomes Study 7-year results
3. A comparison of therapies for the treatment of type 2 diabetes in adolescents (The TODAY Study Group)
4. Metformin (Oral Route) Drug Information

Common questions about Сиофор 500 (FAQ)

Q: Can I become pregnant while taking this drug?

Official product information states that this medicine can cause harm to a developing fetus due to its mechanism of action. Regulatory product information notes that effective contraception is recommended for females of reproductive potential throughout treatment and for up to six months after the last dose.

Q: Does this drug affect male fertility?

According to regulatory documents, this medicine may cause impairment of male fertility, which could be either temporary or permanent. Official labeling states that for males with female partners of reproductive potential, the use of effective contraception is recommended during treatment and for three months after the final dose.

Q: What are the most common side effects?

Regulatory information indicates that the most commonly reported side effects, which occurred in 20% or more of patients during studies, include musculoskeletal pain, inflammation of the mouth (stomatitis), fever (pyrexia), nausea, swelling (edema), infection, and vomiting.

Q: Does this drug cause skin issues?

Studies and official information indicate that this medicine is associated with certain skin issues. These include injection site reactions and local tissue damage (necrosis). If the medicine leaks from the vein (extravasation), effects like redness, pain, and swelling may occur.

Q: Is it safe to exceed the recommended dosage?

Official regulatory warnings indicate that use of a dosage higher than what is recommended for treatment has been associated with an increased risk of severe illness and early mortality.

Q: Does this medicine cause cancer?

Regulatory documents include a warning that there is an increased risk of developing a secondary malignancy, or another type of cancer, that is associated with the use of this medication.

Q: What precautions should I take regarding seizures?

Official product information notes that monitoring for signs of neurological side effects, such as seizures, is necessary for patients identified as being at higher risk. In some clinical situations, preventative treatment (prophylaxis) may be addressed.

How to Store and Dispose of Сиофор 500

The proper storage and disposal of Сиофор 500 (metformin hydrochloride) tablets are defined by regulatory requirements to maintain the medicine's quality and protect the environment.

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 25 C (77°F).
Protection	Keep in the original packaging to protect it from moisture.
Access	Keep this medicine out of the sight and reach of children.
Expiry	Do not use the medicine after the expiry date printed on the packaging.

Disposal Instructions

Do not dispose of this medicine in household waste or flush it down wastewater. To properly discard Сиофор 500 that is no longer needed, consult your pharmacist or local waste disposal service. Following these measures helps protect the environment.